JP2007508020A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007508020A5 JP2007508020A5 JP2006534476A JP2006534476A JP2007508020A5 JP 2007508020 A5 JP2007508020 A5 JP 2007508020A5 JP 2006534476 A JP2006534476 A JP 2006534476A JP 2006534476 A JP2006534476 A JP 2006534476A JP 2007508020 A5 JP2007508020 A5 JP 2007508020A5
- Authority
- JP
- Japan
- Prior art keywords
- clone
- polypeptide
- antibody
- polynucleotide
- spanning positions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 24
- 108090000765 processed proteins & peptides Proteins 0.000 claims 24
- 102000004196 processed proteins & peptides Human genes 0.000 claims 24
- 239000012634 fragment Substances 0.000 claims 19
- 108091033319 polynucleotide Proteins 0.000 claims 19
- 102000040430 polynucleotide Human genes 0.000 claims 19
- 239000002157 polynucleotide Substances 0.000 claims 19
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 18
- 239000002773 nucleotide Substances 0.000 claims 17
- 125000003729 nucleotide group Chemical group 0.000 claims 17
- 210000004027 cell Anatomy 0.000 claims 14
- 238000000034 method Methods 0.000 claims 14
- 101000951345 Homo sapiens Dickkopf-like protein 1 Proteins 0.000 claims 13
- 239000000523 sample Substances 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 11
- 102100037981 Dickkopf-like protein 1 Human genes 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 10
- 239000000427 antigen Substances 0.000 claims 9
- 108091007433 antigens Proteins 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 9
- 150000007523 nucleic acids Chemical class 0.000 claims 9
- 239000000126 substance Substances 0.000 claims 9
- 238000012360 testing method Methods 0.000 claims 9
- 230000000295 complement effect Effects 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 108020004459 Small interfering RNA Proteins 0.000 claims 4
- 239000012867 bioactive agent Substances 0.000 claims 4
- 210000004408 hybridoma Anatomy 0.000 claims 4
- 238000012216 screening Methods 0.000 claims 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 101100277853 Homo sapiens DKKL1 gene Proteins 0.000 claims 2
- 230000001093 anti-cancer Effects 0.000 claims 2
- 239000013068 control sample Substances 0.000 claims 2
- 229940000406 drug candidate Drugs 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 239000004055 small Interfering RNA Substances 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 108700026244 Open Reading Frames Proteins 0.000 claims 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940125648 antineoplastic drug candidate Drugs 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000004520 electroporation Methods 0.000 claims 1
- 230000009368 gene silencing by RNA Effects 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000520 microinjection Methods 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50768203P | 2003-09-30 | 2003-09-30 | |
| PCT/US2004/034256 WO2005033343A2 (en) | 2003-09-30 | 2004-09-30 | Novel splice variants of human dkkl1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007508020A JP2007508020A (ja) | 2007-04-05 |
| JP2007508020A5 true JP2007508020A5 (enExample) | 2007-09-27 |
Family
ID=34421649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006534476A Pending JP2007508020A (ja) | 2003-09-30 | 2004-09-30 | ヒトｄｋｋｌ１の新規スプライス改変体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20070282015A1 (enExample) |
| EP (1) | EP1678325A2 (enExample) |
| JP (1) | JP2007508020A (enExample) |
| CA (1) | CA2540275A1 (enExample) |
| WO (1) | WO2005033343A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2336177A1 (en) | 2004-08-04 | 2011-06-22 | Amgen, Inc | Antibodies to DKK-1 |
| WO2006105343A2 (en) * | 2005-03-30 | 2006-10-05 | Novartis Vaccines And Diagnostics Inc. | Dkkl-i splice product modulators for cancer diagnosis and therapy |
| US8053183B2 (en) * | 2005-07-27 | 2011-11-08 | Oncotherapy Science, Inc. | Method of diagnosing esophageal cancer |
| WO2007104181A1 (en) | 2006-03-13 | 2007-09-20 | Shanghai Cancer Institute | Uses of dkk-1 protein in diagnosis of cancers |
| WO2009028158A1 (en) * | 2007-08-24 | 2009-03-05 | Oncotherapy Science, Inc. | Dkk1 oncogene as therapeutic target for cancer and a diagnosing marker |
| US8143600B2 (en) * | 2008-02-18 | 2012-03-27 | Visiongate, Inc. | 3D imaging of live cells with ultraviolet radiation |
| EP2358898B1 (en) | 2008-11-17 | 2016-08-31 | Headway Technologies, Inc. | Methods and compositions in particle-based detection of target molecules using covalent bond forming reactive pairs |
| WO2010056577A1 (en) * | 2008-11-17 | 2010-05-20 | Magic Technologies, Inc. | Methods and compositions in particle-based detection of target molecules using linking molecules |
| CN101762708B (zh) * | 2008-12-25 | 2014-04-16 | 上海市肿瘤研究所 | 用于诊断非小细胞肺癌的血清标志物 |
| US9447455B2 (en) | 2011-02-16 | 2016-09-20 | Headway Technologies, Inc. | Methods and compositions for the target-localized anchoring of detectable label |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002518010A (ja) * | 1998-06-16 | 2002-06-25 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | ９４個のヒト分泌タンパク質 |
| JP2003528630A (ja) * | 2000-03-28 | 2003-09-30 | カイロン コーポレイション | ヒト遺伝子および発現産物 |
| US20040023241A1 (en) * | 2001-12-05 | 2004-02-05 | Alsobrook John P. | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
-
2004
- 2004-09-30 JP JP2006534476A patent/JP2007508020A/ja active Pending
- 2004-09-30 CA CA002540275A patent/CA2540275A1/en not_active Abandoned
- 2004-09-30 EP EP04789542A patent/EP1678325A2/en not_active Withdrawn
- 2004-09-30 US US10/574,182 patent/US20070282015A1/en not_active Abandoned
- 2004-09-30 WO PCT/US2004/034256 patent/WO2005033343A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009519002A5 (enExample) | ||
| CA2479494A1 (en) | Compositions and methods associated with pro5725 and its use for the diagnosis of lung and colon tumor | |
| JP2010517540A (ja) | 神経変性疾患の診断法 | |
| JP2005027667A5 (enExample) | ||
| JP2007508020A5 (enExample) | ||
| DE50111395D1 (de) | Screeningverfahren | |
| JP7777831B2 (ja) | Ｄｎａポリメラーゼの５’→３’エキソヌクレアーゼ活性ドメインに特異的に結合する抗体 | |
| JP2008535856A5 (enExample) | ||
| JP2001521744A5 (enExample) | ||
| JP2005511023A5 (enExample) | ||
| KR102842664B1 (ko) | 유전자 발현 검정을 이용한 펩티드 수용체 방사선요법의 예측 | |
| WO2023175319A1 (en) | Cancer diagnostics and treatment by means of prmt5 inhibitor | |
| US11667711B2 (en) | Anti-human LAG-3 antibodies and their use in immunohistochemistry (IHC) | |
| WO2013059884A1 (en) | A gene and mutations thereof associated with seizure and movement disorders | |
| JP2009523004A5 (enExample) | ||
| CN118994407A (zh) | 抗噻奈普汀的抗体或其抗原结合片段及其应用 | |
| JP2008535854A5 (enExample) | ||
| JP4967137B2 (ja) | 癌治療用組成物 | |
| JP5407018B2 (ja) | 肺腺癌患者の術後再発を予測するための方法及び組成物 | |
| KR101968962B1 (ko) | 비만 저항성 진단용 조성물 | |
| WO2022108982A1 (en) | Targeting host-bacteria interactions for the treatment of microbiota-mediated diseases | |
| JP2025532064A (ja) | 免疫組織化学（ｉｈｃ）プロトコールにおける使用のためおよびがんを診断するための抗ヒトｉｃｏｓ抗体 | |
| CN117643630A (zh) | 靶向gp73的试剂在动脉粥样硬化中的应用 | |
| CN118339455A (zh) | 调节性t细胞的生物标志物 | |
| CN108456249A (zh) | 变异型α-辅肌动蛋白-4的抗体 |